VRNA - Verona wins FDA approval of ensifentrine for COPD; stock surges 20%
2024-06-26 17:34:28 ET
More on Verona Pharma
- Verona Pharma: Next Week's PDUFA Date Ought To Provide An Upside Catalyst
- Verona Pharma: Key Inflection Point Directly Ahead
- Verona Pharma plc (VRNA) Q1 2024 Earnings Call Transcript
- Verona Pharma gets $650M in financing ahead of June FDA decision on COPD asset
- Verona Pharma GAAP EPS of -$0.04 beats by $0.09